生物医药产业具有技术含量高、开发周期长、风险大等特点,企业发展中可能会遇到技术、资金等方面的门槛。因此,要搞好生物医药产业,还得由政府“推一把”,用创新的办法来推进创新性产业。
大会上,“两个研究院、一个研究中心、一个云平台、一个母子基金”的揭牌,让外界看到烟台在推动生物医药产业发展上的系列“新打法”。
首个揭牌的中科环渤海(烟台)药物高等研究院,是烟台市政府和中科院上海药物研究所共建的新型研发机构,围绕科技创新全链条建设国家级高端生物医药研发一体化平台。烟台生物医药产业创新发展研究院同步揭牌,是由烟台市政府与滨州医学院联合共建的智库型公益性非营利研究机构,以政策研究咨询为主攻方向。显然,烟台在推动生物医药产业发展上,更加注重资源的整合和协同创新,为产业发展赋能。
资本的力量,将在烟台生物医药产业发展中发挥更大的作用。大会现场,烟台迎来“城市合伙人”。大会发布了烟台生物醫药健康产业发展母子基金。母基金总规模100亿元。母基金下设各类子基金,最终形成500亿元规模的母子基金群。母基金成立伊始,即获得了各国内头部股权投资管理机构的大力支持。他们将把烟台作为资源布局的重点区域,全方位融入烟台建设、助推烟台发展。
在产业服务模式上,烟台着力在“精准”上下功夫。山东首个聚焦医药研发生态圈的“一站式”生态服务平台,烟台市生物医药创新发展云平台揭牌。云平台具有政策环境、科研机构、临床资源等十大功能板块,聚集了大量产业资源,为烟台打造特色生物医药产业聚集地提供产业决策和产业服务的数智平台。
推进数字融合,是烟台打造生物医药产业的一大亮点。由烟台市政府与软件开发环境国家重点实验室、滨州医学院三方共建的烟台市医药健康区块链研究中心揭牌,致力于打造成以医疗健康为主的区块链技术和生态应用模式的科技创新、人才培养和应用服务基地,构建具有领先水平的健康区块链产业生态。
在全球抗疫这场特殊背景下举办的2021医药创新与发展国际会议,为全球生物医药产业发展作出了有益探讨,也必将为烟台打造生命科学创新示范城市注入新动能。
Health is the eternal theme of mankind. In face of the pandemic, vaccines and effective medicine become the key and the strategic value of pharmaceutical and healthcare industry is better highlighted.
As an important locus of the pharmaceutical industry in China, Yantai becomes a spotlight again. On Jul.29, the International Conference on Pharmaceutical Innovation and Development 2021 was opened ceremoniously in Yantai. Attended by national ministries and commissions, professional associations, heads of relevant departments in Shandong Province, academicians from Chinese Academy of Sciences and Chinese Academy of Engineering, international experts and scholars in the field of biopharmacy and reputed entrepreneurs, the conference gathered professional elites, who jointly explored the new direction for the development of the biopharmaceutical industry and worked on Yantai Plan for Healthy China.
The industrial conference is both a platform for industrial exchanges and cooperation and a reflection of the ambition of a city for development. In the conference, CPC Yantai Municipal Committee and Yantai Municipal Government publicized with authority their thoughts, aim and ways to further the development of the biopharmaceutical industry and policies to ensure its development, claiming they would expand and strengthen the industrial chain and accelerate the construction of the vertical ecological system in the biopharmaceutical industry with a view to achieve the income of over 200 billion yuan in the primary business of the biopharmaceutical industry and become a demonstration city in innovation in life sciences with significant influence and competitive power at home and abroad by 2023.
Yantai is planning a new way to advance the industry by mapping a panorama for the biopharmaceutical industry. It takes integrative actions for industrial development by laying out a “1+3+X” biopharmaceutical industrial park, establishing “two research institutes, a research center, a cloud platform and a FOF (Fund of Funds),” signing 26 projects with a total investment of 22.31 billion yuan, and making a one-off distribution of monetary reward at 90 million yuan in support of innovative development.
Yantai is on the way to forge an innovative biopharmaceutical valley in China.